Mineralocorticoid Receptor Antagonists
The competitive antagonists of the aldosterone (or mineralocorticoid) receptor, spironolactone and eplerenone, reduce mortality and hospitalizations in patients with New York Heart Association (NYHA) functional class II to IV HFrEF and in those with an LVEF <40% after an acute myocardial infarction. 69–71 The effect of these agents on quality of life and exercise tolerance has not been well documented. Continue reading “Such representatives is contraindicated in the clients with stage IV otherwise V persistent kidney state who aren’t in the process of dialysis”